JP2009544705A - がんの治療のために有用なｍｋ−０４５７の新規乳酸製剤 - Google Patents

がんの治療のために有用なｍｋ−０４５７の新規乳酸製剤 Download PDF

Info

Publication number
JP2009544705A
JP2009544705A JP2009521803A JP2009521803A JP2009544705A JP 2009544705 A JP2009544705 A JP 2009544705A JP 2009521803 A JP2009521803 A JP 2009521803A JP 2009521803 A JP2009521803 A JP 2009521803A JP 2009544705 A JP2009544705 A JP 2009544705A
Authority
JP
Japan
Prior art keywords
inhibitors
lactic acid
cancer
agents
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009521803A
Other languages
English (en)
Japanese (ja)
Inventor
デュボスト，デイビッド，シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2009544705A publication Critical patent/JP2009544705A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009521803A 2006-07-26 2007-07-24 がんの治療のために有用なｍｋ−０４５７の新規乳酸製剤 Withdrawn JP2009544705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83344206P 2006-07-26 2006-07-26
PCT/US2007/016637 WO2008013807A2 (en) 2006-07-26 2007-07-24 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer

Publications (1)

Publication Number Publication Date
JP2009544705A true JP2009544705A (ja) 2009-12-17

Family

ID=38863098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521803A Withdrawn JP2009544705A (ja) 2006-07-26 2007-07-24 がんの治療のために有用なｍｋ−０４５７の新規乳酸製剤

Country Status (6)

Country Link
EP (1) EP2051737A2 (zh)
JP (1) JP2009544705A (zh)
CN (1) CN101500613A (zh)
AU (1) AU2007277226A1 (zh)
CA (1) CA2658436A1 (zh)
WO (1) WO2008013807A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283482B1 (en) * 2015-04-17 2022-04-06 Ludwig Institute for Cancer Research Ltd Plk4 inhibitors
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014250A2 (en) * 2005-07-26 2007-02-01 Vertex Pharmaceuticals Incorporated Abl kinase inhibition
WO2007136615A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Combination cancer therapy

Also Published As

Publication number Publication date
WO2008013807A2 (en) 2008-01-31
WO2008013807A9 (en) 2009-03-12
CN101500613A (zh) 2009-08-05
AU2007277226A1 (en) 2008-01-31
CA2658436A1 (en) 2008-01-31
EP2051737A2 (en) 2009-04-29
WO2008013807A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
US20090227598A1 (en) Ret Tyrosine Kinase Inhibition
EP2755482B1 (en) Combination of mk-1775 and mk-8776 for treating cancer
RU2660429C2 (ru) Новые соединения, которые являются ингибиторами erk
US20140349968A1 (en) Compositions and Methods for Treating Cancer
US20210309687A1 (en) Prmt5 inhibitors
JP2023507634A (ja) Ｐｒｍｔ５阻害剤
EP1885349B1 (en) Sulphamides for treatment of cancer
US20090215775A1 (en) Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
US11981701B2 (en) PRMT5 inhibitors
US20090105270A1 (en) Kinase inhibition and anticancer therapy
US8362075B2 (en) Cyclohexyl sulphones for treatment of cancer
JP2009544705A (ja) がんの治療のために有用なｍｋ−０４５７の新規乳酸製剤
US9546168B2 (en) ERK inhibitors
US20100324063A1 (en) Jak2 tyrosine kinase inhibition
JP2023508137A (ja) Ｐｒｍｔ５阻害剤
US20090306058A1 (en) Sulphone Derivatives for Treatment of Cancer

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20101005